Quest Diagnostics (DGX) Q3 FY2025 earnings: revenue $2.8 billion, up 13.2% on the year
Quest Diagnostics Inc. (DGX) reported revenue of $2.8 billion for Q3 FY2025, the quarter ended 30 September 2025, up 13.2% on the same quarter a year earlier. Net income was $245 million, up 8.4% on the year, and diluted earnings per share $2.16. The figures are the company's own, from the 10-Q it filed with the SEC on 21 October 2025.
Revenue
$2.8 billion
+13.2% on the year · +2.0% on the quarter
Q4 FY2023Q3 FY2025
Operating margin
13.7%
13.3% a year earlier
Q4 FY2023Q3 FY2025
Net income
$245 million
+8.4% on the year · -13.1% on the quarter
Q4 FY2023Q3 FY2025
Diluted EPS
$2.16
+8.5% on the year · -12.6% on the quarter
Q4 FY2023Q3 FY2025
this quarterthe same quarter a year earlierHover a bar for its figure.
Income statement (profit and loss)
$ million
Q3 FY2025
Q2 FY2025
Q3 FY2024
On the quarter
On the year
Last 8 quarters
Revenue
2,816
2,761
2,488
+2.0%
+13.2%
Cost of revenue
1,867
1,818
1,677
+2.7%
+11.3%
Gross profit
949
943
811
+0.6%
+17.0%
Gross margin
33.7%
34.2%
32.6%
Selling, general and administrative
501
486
448
+3.1%
+11.8%
Operating income
386
438
330
-11.9%
+17.0%
Operating margin
13.7%
15.9%
13.3%
Interest expense
66.0
67.0
49.0
-1.5%
+34.7%
Pre-tax income
328
384
296
-14.6%
+10.8%
Income tax
77.0
97.0
65.0
-20.6%
+18.5%
Effective tax rate
23.5%
25.3%
22.0%
Net income
245
282
226
-13.1%
+8.4%
Net margin
8.7%
10.2%
9.1%
Diluted EPS
$2.16
$2.47
$1.99
-12.6%
+8.5%
$ million except per share. Read moreFree cash flow is operating cash flow less capital expenditure; the effective tax rate is income tax over pre-tax income; margins are the line over revenue. Gross profit is revenue less cost of revenue, and operating income is revenue less the company's own total costs, where the statement does not print those lines. Those four are arithmetic on the filed numbers; everything else is as filed. Money is in $ million as the company files it, or in $ billion by the switch above the tables; per share figures and share counts are as they are.
Cash flow
$ million
Q3 FY2025
Q2 FY2025
Q3 FY2024
On the quarter
On the year
Last 8 quarters
Operating cash flow
563
544
356
+3.5%
+58.1%
Capital expenditure
144
108
106
+33.3%
+35.8%
Free cash flow
419
436
250
-3.9%
+67.6%
Free cash flow margin
14.9%
15.8%
10.0%
Cash from investing
-201
-124
-1,633
Cash from financing
-247
-293
1,770
Depreciation and amortisation
142
143
125
-0.7%
+13.6%
Share-based compensation
20.0
21.0
19.0
-4.8%
+5.3%
Buybacks
150
n/a
n/a
Dividends paid
89.0
90.0
84.0
-1.1%
+6.0%
Dividend per share
$0.80
$0.80
$0.75
0.0%
+6.7%
Diluted shares, weighted
113m
113m
113m
0.0%
0.0%
Shares outstanding at period end
111m
112m
112m
-0.5%
-0.3%
Cash flow lines for the quarter; where the company files them year to date, the quarter is the difference between two filings.
Balance sheet
$ million
Q3 FY2025
Q2 FY2025
Q3 FY2024
On the quarter
On the year
Last 8 quarters
Shareholders' equity
7,258
7,228
6,809
+0.4%
+6.6%
Non-controlling interest
37.0
37.0
32.0
0.0%
+15.6%
Redeemable equity
81.0
81.0
80.0
0.0%
+1.2%
Debt
5,675
5,673
6,251
+0.0%
-9.2%
Operating lease liabilities
534
540
543
-1.1%
-1.7%
Other liabilities
2,612
2,410
2,380
+8.4%
+9.7%
Total liabilities and equity
16,197
15,969
16,095
+1.4%
+0.6%
Fixed assets
2,145
2,120
2,093
+1.2%
+2.5%
Goodwill
8,901
8,883
8,605
+0.2%
+3.4%
Intangible assets
1,662
1,706
1,716
-2.6%
-3.1%
Cash and equivalents
432
319
764
+35.4%
-43.5%
Receivables
1,456
1,419
1,376
+2.6%
+5.8%
Inventory
186
187
184
-0.5%
+1.1%
Other assets
1,415
1,335
1,357
+6.0%
+4.3%
Total assets
16,197
15,969
16,095
+1.4%
+0.6%
Questions
What was Quest Diagnostics' revenue in Q3 FY2025?
Quest Diagnostics (DGX) reported revenue of $2.8 billion for Q3 FY2025, the quarter ended 30 September 2025, up 13.2% on the same quarter a year earlier.
How much did Quest Diagnostics earn in Q3 FY2025?
Net income for Q3 FY2025 was $245 million, up 8.4% on the year, and diluted earnings per share $2.16.
When did Quest Diagnostics report Q3 FY2025 results?
Quest Diagnostics filed its 10-Q for the quarter ended 30 September 2025 with the SEC on 21 October 2025.
Each quarter as filed, linked to its filing. Read more* The fourth quarter is the full year less the first three quarters, because the company files the year and not the quarter on its own. A fourth quarter's EPS, and its diluted share count where shown, are from the company's results press release for that quarter, checked against the company's filed figures or a second data source. Money is in $ million as the company files it, or in $ billion by the switch above the tables; per share figures and the share count are as they are. Free cash flow is operating cash flow less capital expenditure; the effective tax rate is income tax over pre-tax income; margins are the line over revenue. Gross profit is revenue less cost of revenue, and operating income is revenue less the company's own total costs, where the statement does not print those lines. Cash flow lines filed year to date are the difference between two filings. Shares outstanding are at the period end where the balance sheet tags them, otherwise the count on the filing's cover page. A derived fourth-quarter EPS is left blank when a split in the year makes the arithmetic meaningless.
10-Q for the period ended 30 September 2025, filed 21 October 2025: the filing.